Novacyt S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALNOV.PA | QTI | TRIB | VNRX | ALERS.PA | QDEL | |
|---|---|---|---|---|---|---|
| Market cap | 30.89M | 32.05M | 5.23M | 6.11M | 265.30M | 984.06M |
| P/E (TTM) | — | — | — | — | 37.6 | — |
| Forward P/E | 1.6 | -14.6 | -6.2 | -0.2 | 23.3 | 10.1 |
| Price/book | 1.4 | 13.4 | -0.1 | -0.1 | 1.4 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −7.11% | −67.71% | −77.91% | −97.79% | +9.56% | −32.50% |
| Today | +0.12% | +1.39% | −2.02% | +5.23% | 0.00% | +1.85% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All ALNOV.PA news ›Novacyt's strikes Illumina deal; Beeks' Thailand deal
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Novacyt SA - biotechnology group focused on clinical... Biotechnology & Medical Research…
REG - Novacyt S.A. - Liquidity Agreement Monthly Update and TVR
(“Novacyt”, the “Company” or the “Group”) Liquidity Agreement Monthly Update and Total Voting Rights Lyn Rees, Chief Executive Officer Steve Gibson, Chief Financial Officer SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.